Speaker
Description
Context and Rationale: Quercetin (QCE), a flavonoid found in foods, is a member of the polyphenol family and is derived mainly from plant and fruit sources. QCE is a natural antioxidant that suppresses the excessive generation of reactive oxygen species (ROS) inside the cellular microenvironment. Therefore, it may treat various medical conditions, including cancer, infections, inflammation, and more. Because of its poor solubility and permeability, it has just a few applications. It is also poorly absorbed when used orally. To improve the solubility, permeability, and therapeutic effectiveness of QCE, we integrated it into a biopolymer beta-cyclodextrin inclusion complex (QCE-SBE-β-CD) in this work.
Methodology: Using the traditional kneading approach, the QCE-SBE-β-CD was created by optimizing the numerous aspects and variables. The QCE-SBE-β-CD was assessed further for phase solubility investigations to determine the accuracy of the drug-polymer conjugation, the binding affinity, and the stability characteristics. As media for phase solubility investigations, water (aqueous medium) and simulated nasal fluid (SNF; pH 5.5) were used.
Results and analysis: The results of the phase solubility investigations indicated that at room temperature, the ΔH and ΔS values of QCE-SBE-β-CD in an aqueous medium were 14.92±0.98 J/Mole and 108.38±2.94 J/Mole.K, respectively and the ΔH and ΔS values of QCE-SBE-β-CD in SNF (pH 5.5) were measured to be 15.54 ± 0.16 J/Mole and 140.70± 0.45 J/Mole.K, respectively. These results are essential in developing innovative intranasal treatments, primarily used to provide medicines that aren't highly water-soluble.
Conclusion: Results indicated that nasal injection of QCE-SBE-β-CD would be more effective for medicine targeting because of the compound's higher binding affinity in SNF, leading to greater bioavailability and less toxicity.